ECSP22038978A - INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA - Google Patents

INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA

Info

Publication number
ECSP22038978A
ECSP22038978A ECSENADI202238978A ECDI202238978A ECSP22038978A EC SP22038978 A ECSP22038978 A EC SP22038978A EC SENADI202238978 A ECSENADI202238978 A EC SENADI202238978A EC DI202238978 A ECDI202238978 A EC DI202238978A EC SP22038978 A ECSP22038978 A EC SP22038978A
Authority
EC
Ecuador
Prior art keywords
alpha4ß7
inhibition
human integrin
integrin
human
Prior art date
Application number
ECSENADI202238978A
Other languages
English (en)
Inventor
Bryce A Harrison
Evelyne Houang
Salma Rafi
Robert Zahler
Cheng Zhong
fu-yang Lin
Aleksey I Gerasyuto
Tyler Day
Byungchan Kim
Bruce N Rogers
James E Dowling
Blaise S Lippa
Eugene Hickey
Dan Cui
Kyle D Konze
Dawn M Troast
Kristopher N Hahn
Matthew G Bursavich
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of ECSP22038978A publication Critical patent/ECSP22038978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Moléculas pequeñas antagonistas de la integrina humana Alfa4ß7, y métodos para usarlas en el tratamiento de varias enfermedades y afecciones.
ECSENADI202238978A 2019-10-16 2022-05-16 INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA ECSP22038978A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
ECSP22038978A true ECSP22038978A (es) 2022-06-30

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202238978A ECSP22038978A (es) 2019-10-16 2022-05-16 INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA

Country Status (22)

Country Link
US (3) US20240174632A1 (es)
EP (2) EP4045039A4 (es)
JP (5) JP7437490B2 (es)
KR (2) KR20220102669A (es)
CN (2) CN115087444A (es)
AR (1) AR120244A1 (es)
AU (2) AU2020366435A1 (es)
BR (1) BR112022007284A2 (es)
CA (1) CA3154269A1 (es)
CL (1) CL2022000959A1 (es)
CO (1) CO2022005759A2 (es)
CR (1) CR20220205A (es)
CU (1) CU20220027A7 (es)
DO (1) DOP2022000081A (es)
EC (1) ECSP22038978A (es)
IL (1) IL292296A (es)
MX (1) MX2022004406A (es)
PE (1) PE20221829A1 (es)
TW (4) TWI775182B (es)
UY (1) UY38926A (es)
WO (3) WO2021076890A1 (es)
ZA (1) ZA202203872B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
CN115087444A (zh) 2019-10-16 2022-09-20 莫菲克医疗股份有限公司 抑制人整联蛋白α4β7
WO2023125182A1 (zh) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 一种丙酸衍生物及其在医药上的应用
WO2024051819A1 (zh) * 2022-09-09 2024-03-14 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691953B1 (en) 1993-03-31 2000-08-02 G.D. Searle & Co. 1-amidinophenyl-pyrrolidones/ piperidinones as platelet aggregation inhibitors
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ATE267168T1 (de) 1997-11-24 2004-06-15 Merck & Co Inc Beta-alanin-derivate als zell-adhäsions- inhibitoren
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2333647A1 (en) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CZ304225B6 (cs) * 1999-05-07 2014-01-15 Encysive Pharmaceuticals Inc. Deriváty kyseliny propionové, které inhibují vazbu integrinů na jejich receptory
WO2001021584A1 (en) 1999-09-24 2001-03-29 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
BR0113671A (pt) * 2000-08-30 2004-01-06 Pharmacia Corp Antagonistas de integrina alfa v beta 3 gem-substituìda
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
EP3173426A1 (en) 2002-02-25 2017-05-31 Biogen MA Inc. Administration of agents for the treatment of inflammation
LT3530673T (lt) 2004-09-03 2022-06-10 Genentech, Inc. Humanizuoti anti-beta7 antagonistai ir jų panaudojimas
US7972775B2 (en) 2005-03-03 2011-07-05 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing Natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EA013080B1 (ru) 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2010091411A1 (en) 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
JP6248029B2 (ja) 2011-03-31 2017-12-13 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストの投与方法
CN104870056A (zh) 2012-10-05 2015-08-26 弗·哈夫曼-拉罗切有限公司 用于诊断和治疗炎性肠病的方法
MX2016012282A (es) 2014-03-27 2017-01-06 Genentech Inc Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
WO2016011940A1 (zh) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
AR103782A1 (es) 2015-02-26 2017-05-31 Genentech Inc ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
KR102605460B1 (ko) * 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373245C1 (en) * 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
KR102652797B1 (ko) * 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린의 억제를 위한 화합물
CN115087444A (zh) 2019-10-16 2022-09-20 莫菲克医疗股份有限公司 抑制人整联蛋白α4β7

Also Published As

Publication number Publication date
CA3154269A1 (en) 2021-04-22
US11370773B1 (en) 2022-06-28
CL2022000959A1 (es) 2023-04-28
JP2022542184A (ja) 2022-09-29
TW202315868A (zh) 2023-04-16
JP2023036958A (ja) 2023-03-14
MX2022004406A (es) 2022-08-25
CU20220027A7 (es) 2022-12-12
JP2024054293A (ja) 2024-04-16
TWI802477B (zh) 2023-05-11
WO2022081983A1 (en) 2022-04-21
WO2021076902A1 (en) 2021-04-22
EP4045039A4 (en) 2023-12-13
PE20221829A1 (es) 2022-11-29
KR20230088376A (ko) 2023-06-19
TW202332675A (zh) 2023-08-16
AU2021361031A1 (en) 2023-06-08
WO2021076890A4 (en) 2021-06-10
JP2022548809A (ja) 2022-11-22
JP7209116B2 (ja) 2023-01-19
TW202126624A (zh) 2021-07-16
TW202222793A (zh) 2022-06-16
WO2021076890A1 (en) 2021-04-22
AU2020366435A1 (en) 2022-04-21
TWI775182B (zh) 2022-08-21
JP2024054296A (ja) 2024-04-16
JP7437495B2 (ja) 2024-02-22
US20240174632A1 (en) 2024-05-30
KR20220102669A (ko) 2022-07-20
DOP2022000081A (es) 2022-07-31
TW202244040A (zh) 2022-11-16
EP4228634A1 (en) 2023-08-23
JP7437490B2 (ja) 2024-02-22
EP4045039A1 (en) 2022-08-24
IL292296A (en) 2022-06-01
BR112022007284A2 (pt) 2022-07-05
JP2023500437A (ja) 2023-01-06
CO2022005759A2 (es) 2022-05-20
US11104661B1 (en) 2021-08-31
ZA202203872B (en) 2024-01-31
TWI791304B (zh) 2023-02-01
CR20220205A (es) 2022-07-22
UY38926A (es) 2021-05-31
AR120244A1 (es) 2022-02-09
CN115087444A (zh) 2022-09-20
CN116783161A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
SV2018005610A (es) Derivados de oxopiridina sustituidos
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UY38353A (es) Inhibición de integrina alfavbeta6
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2016001895A1 (es) Compuestos
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
EA201991214A1 (ru) Антитела против pd-1 и их композиции
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2013000047A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
CR11795A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
CL2015002835A1 (es) Nuevos derivados de piridina
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου